Načítá se...
CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
Tacrolimus is a commonly used immunosuppressant after kidney transplantation. It has a narrow therapeutic range and demonstrates wide interindividual variability in pharmacokinetics, leading to potential underimmunosuppression or toxicity. Genetic polymorphism in CYP3A5 enzyme expression contributes...
Uloženo v:
| Vydáno v: | Pharmgenomics Pers Med |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5846312/ https://ncbi.nlm.nih.gov/pubmed/29563827 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S107710 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|